RPS6KB1 and lung adenocarcinoma: We also evaluated the expression of total and phosphorylated p70S6K in clinical EGFR TKI-sensitive and -resistant lung adenocarcinoma tumor tissues and found that p70S6K may be a good marker for selection of patients for whom ku-0063794 therapy is appropriate.